Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 28 February 2007. doi:10.1136/adc.2006.098566
Archives of Disease in Childhood - Fetal and Neonatal Edition 2007;92:F367-F371
Copyright © 2007 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health.

ORIGINAL ARTICLE

Dopamine versus dobutamine in very low birthweight infants: endocrine effects

Luca Filippi1, Marco Pezzati2, Chiara Poggi1, Sauro Rossi3, Alessandra Cecchi1 and Cristina Santoro1

1 Neonatal Intensive Care Unit, Department of Critical Care Medicine, Meyer University Hospital, Florence, Italy
2 Neonatal Intensive Care Unit, San Giovanni di Dio Hospital, Florence, Italy
3 Neonatal Intensive Care Unit, Department of Critical Care Medicine, Careggi University Hospital Florence, Italy

Correspondence to:
Dr Luca Filippi, Neonatal Intensive Care Unit, Department of Critical Care Medicine, Meyer University Hospital, via L. Giordano, 13 I-50132 Florence, Italy; filippi.luca{at}virgilio.it

Objectives: To compare the endocrine effects of dopamine and dobutamine in hypotensive very low birthweight (VLBW) infants.

Design: Non-blinded randomised prospective trial.

Setting: Level III neonatal intensive care unit.

Patients: 35 hypotensive VLBW infants who did not respond to volume loading, assigned to receive dopamine or dobutamine.

Measurements: Haemodynamic variables and serum levels of thyroid stimulating hormone (TSH), total thyroxine (T4), prolactin (PRL) and growth hormone were assessed during the first 72 h of treatment and the first 72 h after stopping treatment.

Results: Demographic and clinical data did not significantly differ between the two groups. Necessary cumulative and mean drug doses and maximum infusion required to normalise blood pressure were significantly higher in the dobutamine than in the dopamine group (p<0.01). Suppression of TSH, T4 and PRL was observed in dopamine-treated newborns from 12 h of treatment onwards, whereas levels of growth hormone reduced significantly only at 12 h and 36 h of treatment (p<0.01). TSH, T4 and PRL rebound was observed from the first day onwards after stopping dopamine. Dobutamine administration did not alter the profile of any of the hormones and no rebound was observed after stopping treatment.

Conclusion: Dopamine and dobutamine both increase the systemic blood pressure, though dopamine is more effective. Dopamine reduces serum levels of TSH, T4 and PRL in VLBW infants but such suppression is quickly reversed after treatment is stopped. Further research is required to assess if short-term iatrogenic pituitary suppression has longer-term consequences.

Keywords: dopamine; dobutamine; preterm newborn; hypotension


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

eLetters:

Read all eLetters

Inotropes and cyanotic skin rash: worrisome side effects of dopamine.
Stefano Maccario, et al.
Fetal Neonatal Ed. Online, 3 Dec 2008 [Full text]

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Latest from ADC

 

ADC is co-owned by the RCPCH and is the official journal of the European Academy of Paediatrics

BMJ Careers - Latest Paediatrics and Paediatric Surgery Jobs

Paediatrics and Paediatric Surgery Jobs